Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hepatology Reports
Erschienen in: Current Hepatology Reports 4/2016

20.07.2016 | Hepatitis B (JK Lim, Section Editor)

Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus

verfasst von: Blanca Lizaola, Alan Bonder, Elliot B. Tapper, Nezam Afdhal

Erschienen in: Current Hepatology Reports | Ausgabe 4/2016

Einloggen, um Zugang zu erhalten

Abstract

Chronic hepatitis B represents a major public health burden. One quarter of patients with chronic hepatitis B will progress to cirrhosis without treatment. According to the current hepatitis B guidelines, treatment is based upon alanine aminotransferase (ALT) elevation and hepatitis B virus (HBV) DNA levels, along with liver fibrosis staging. Liver biopsy still represents the gold standard for the diagnosis and staging of liver fibrosis. However, this method has several limitations like invasiveness, sampling variations, pain, time commitments, and bleeding. In response to this concern, in the last decade, a large amount of noninvasive methods have emerged offering promising diagnostic capabilities. These techniques include serum markers of fibrosis and radiological tests. In the present review, we discuss the performance characteristics and advantages of using noninvasive methods to diagnose and stage liver fibrosis in patients with chronic hepatitis B and its utility in clinical practice.
Literatur
1.
Lozano R et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.CrossRefPubMed
2.
3.
Ganem D, Prince AM. Hepatitis B virus infection—natural history and clinical consequences. N Engl J Med. 2004;350(11):1118–29.CrossRefPubMed
4.
Fattovich G. Natural history and prognosis of hepatitis B. Semin Liver Dis. 2003;23(1):47–58.CrossRefPubMed
5.
Yim HJ, Lok AS. Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know in 2005. Hepatology. 2006;43(2 Suppl 1):S173–81.CrossRefPubMed
6.
McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(5 Suppl):S45–55.CrossRefPubMed
7.
Massarrat S, Fallahazad V, Kamalian N. Clinical, biochemical and imaging-verified regression of hepatitis B-induced cirrhosis. Liver Int. 2004;24(2):105–9.CrossRefPubMed
8.
Terrault NA et al. AASLD guidelines for treatment of chronic hepatitis B. Hepatology. 2016;63(1):261–83.CrossRefPubMed
9.
Lai M et al. The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol. 2007;47(6):760–7.CrossRefPubMed
10.
WHO guidelines approved by the Guidelines Review Committee, in Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. 2015, World Health Organization. Copyright (c) World Health Organization 2015.: Geneva.
11.
Chon YE et al. Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One. 2012;7(9):e44930.CrossRefPubMedPubMedCentral
12.
Bonder A, Tapper EB, Afdhal NH. Contemporary assessment of hepatic fibrosis. Clin Liver Dis. 2015;19(1):123–34.CrossRefPubMed
13.
Rouviere O et al. MR elastography of the liver: preliminary results. Radiology. 2006;240(2):440–8.CrossRefPubMed
14.
Muthupillai R et al. Magnetic resonance elastography by direct visualization of propagating acoustic strain waves. Science. 1995;269(5232):1854–7.CrossRefPubMed
15.
Lee Y et al. MR elastography for noninvasive assessment of hepatic fibrosis: reproducibility of the examination and reproducibility and repeatability of the liver stiffness value measurement. J Magn Reson Imaging. 2014;39(2):326–31.CrossRefPubMed
16.
Venkatesh SK et al. Magnetic resonance elastography of liver in healthy Asians: normal liver stiffness quantification and reproducibility assessment. J Magn Reson Imaging. 2014;39(1):1–8.CrossRefPubMed
17.
Hines CD et al. Effects of postprandial state and mesenteric blood flow on the repeatability of MR elastography in asymptomatic subjects. J Magn Reson Imaging. 2011;33(1):239–44.CrossRefPubMed
18.
Herzka DA et al. Magnetic resonance elastography in the liver at 3 Tesla using a second harmonic approach. Magn Reson Med. 2009;62(2):284–91.CrossRefPubMed
19.
Mannelli L et al. Magnetic resonance elastography: feasibility of liver stiffness measurements in healthy volunteers at 3T. Clin Radiol. 2012;67(3):258–62.CrossRefPubMed
20.
Kim BH et al. MR elastography for noninvasive assessment of hepatic fibrosis: experience from a tertiary center in Asia. J Magn Reson Imaging. 2011;34(5):1110–6.CrossRefPubMed
21.
Venkatesh SK, Yin M, Ehman RL. Magnetic resonance elastography of liver: technique, analysis, and clinical applications. J Magn Reson Imaging. 2013;37(3):544–55.CrossRefPubMedPubMedCentral
22.
Lee VS et al. Magnetic resonance elastography and biomarkers to assess fibrosis from recurrent hepatitis C in liver transplant recipients. Transplantation. 2011;92(5):581–6.CrossRefPubMed
23.
Wu WP et al. Non-invasive evaluation of hepatic fibrosis: the diagnostic performance of magnetic resonance elastography in patients with viral hepatitis B or C. PLoS One. 2015;10(10):e0140068.CrossRefPubMedPubMedCentral
24.
Venkatesh SK et al. Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol. 2014;24(1):70–8.CrossRefPubMed
25.••
Singh S et al. Diagnostic performance of magnetic resonance elastography in staging liver fibrosis: a systematic review and meta-analysis of individual participant data. Clin Gastroenterol Hepatol. 2015;13(3):440–451.e6. MRE has high diagnostic accuracy for significant or advanced fibrosis and cirrhosis, independent of BMI and etiology of chronic liver disease.CrossRefPubMed
26.
27.
Bensamoun SF et al. Measurement of liver stiffness with two imaging techniques: magnetic resonance elastography and ultrasound elastometry. J Magn Reson Imaging. 2008;28(5):1287–92.CrossRefPubMed
28.
Lee JE et al. Noninvasive assessment of hepatic fibrosis in patients with chronic hepatitis B viral infection using magnetic resonance elastography. Korean J Radiol. 2014;15(2):210–7.CrossRefPubMedPubMedCentral
29.
Friedrich-Rust M et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology. 2009;252(2):595–604.CrossRefPubMed
30.
Bota S et al. The influence of aminotransferase levels on liver stiffness assessed by Acoustic Radiation Force Impulse Elastography: a retrospective multicentre study. Dig Liver Dis. 2013;45(9):762–8.CrossRefPubMed
31.
Lupsor M et al. Performance of a new elastographic method (ARFI technology) compared to unidimensional transient elastography in the noninvasive assessment of chronic hepatitis C. Preliminary results. J Gastrointestin Liver Dis. 2009;18(3):303–10.PubMed
32.
Sporea I et al. How efficient is acoustic radiation force impulse elastography for the evaluation of liver stiffness? Hepat Mon. 2011;11(7):532–8.PubMedPubMedCentral
33.
Sporea I et al. Acoustic Radiation Force Impulse elastography for fibrosis evaluation in patients with chronic hepatitis C: an international multicenter study. Eur J Radiol. 2012;81(12):4112–8.CrossRefPubMed
34.
Fierbinteanu-Braticevici C et al. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis. World J Gastroenterol. 2009;15(44):5525–32.CrossRefPubMedPubMedCentral
35.
Friedrich-Rust M et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat. 2012;19(2):e212–9.CrossRefPubMed
36.
Yoneda M et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology. 2010;256(2):640–7.CrossRefPubMed
37.
Rizzo L et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol. 2011;106(12):2112–20.CrossRefPubMed
38.
Sporea I et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall Med. 2011;32 Suppl 1:S46–52.CrossRefPubMed
39.
Nierhoff J et al. The efficiency of acoustic radiation force impulse imaging for the staging of liver fibrosis: a meta-analysis. Eur Radiol. 2013;23(11):3040–53.CrossRefPubMed
40.•
Salkic NN et al. FibroTest/Fibrosure for significant liver fibrosis and cirrhosis in chronic hepatitis B: a meta-analysis. Am J Gastroenterol. 2014;109(6):796–809. FibroTest is of value in exclusion of patients with CHB-related cirrhosis, but has suboptimal accuracy in the detection of significant fibrosis and cirrhosis. Considers combining it with other noninvasive modalities in order to improve accuracy.CrossRefPubMed
41.
Poynard T et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol. 2004;3(1):8.CrossRefPubMedPubMedCentral
42.
Leroy V et al. Prospective evaluation of FibroTest(R), FibroMeter(R), and HepaScore(R) for staging liver fibrosis in chronic hepatitis B: comparison with hepatitis C. J Hepatol. 2014;61(1):28–34.CrossRefPubMed
43.
Sandrin L et al. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003;29(12):1705–13.CrossRefPubMed
44.
Tapper EB, Castera L, Afdhal NH. FibroScan (vibration-controlled transient elastography): where does it stand in the United States practice. Clin Gastroenterol Hepatol. 2015;13(1):27–36.CrossRefPubMed
45.
Tapper EB, Afdhal NH. Vibration-controlled transient elastography: a practical approach to the noninvasive assessment of liver fibrosis. Curr Opin Gastroenterol. 2015;31(3):192–8.CrossRefPubMed
46.
Pradhan F et al. Feasibility and reliability of the FibroScan S2 (pediatric) probe compared with the M probe for liver stiffness measurement in small adults with chronic liver disease. Ann Hepatol. 2013;12(1):100–7.PubMed
47.
Wong VW et al. Liver stiffness measurement using XL probe in patients with nonalcoholic fatty liver disease. Am J Gastroenterol. 2012;107(12):1862–71.CrossRefPubMed
48.
Arena U et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology. 2013;58(1):65–72.CrossRefPubMed
49.
Lebray P et al. Liver stiffness is an unreliable marker of liver fibrosis in patients with cardiac insufficiency. Hepatology. 2008;48(6):2089.CrossRefPubMed
50.
Cardoso AC et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int. 2012;32(4):612–21.CrossRefPubMed
51.
Marcellin P et al. Non-invasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. Liver Int. 2009;29(2):242–7.CrossRefPubMed
52.
Malik R et al. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol. 2010;25(9):1562–8.CrossRefPubMed
53.
Chan HL et al. Alanine aminotransferase-based algorithms of liver stiffness measurement by transient elastography (Fibroscan) for liver fibrosis in chronic hepatitis B. J Viral Hepat. 2009;16(1):36–44.CrossRefPubMed
54.••
Li Y. et al. Development of algorithms based on serum markers and Fibroscan for detecting significant fibrosis and cirrhosis in chronic hepatitis B patients: significant reduction in liver biopsy. Hepatol Res. 2016. The combination on APRI + FS and FIB-4 + FS algorithms could significantly reduce the need for liver biopsy with high accuracy, sensitivity and positive predictive value for diagnosis of significant fibrosis and cirrhosis in CHB patients.
55.
Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16(2):372.CrossRefPubMed
56.
Cassinotto C et al. Non-invasive assessment of liver fibrosis with impulse elastography: comparison of Supersonic Shear Imaging with ARFI and FibroScan(R). J Hepatol. 2014;61(3):550–7.CrossRefPubMed
57.
Park MS et al. Factors influencing the diagnostic accuracy of acoustic radiation force impulse elastography in patients with chronic hepatitis B. Gut Liver. 2016;10(2):275–82.CrossRefPubMed
58.
Bota S et al. Spleen assessment by Acoustic Radiation Force Impulse Elastography (ARFI) for prediction of liver cirrhosis and portal hypertension. Med Ultrason. 2010;12(3):213–7.PubMed
59.•
Cabassa P et al. Acoustic radiation force impulse quantification of spleen elasticity for assessing liver fibrosis. Abdom Imaging. 2015;40(4):738–44. Spleen ARFI has the potential to discriminate early from severe liver fibrosis. Spleen and liver ARFI, when combined, show a better discriminative power than liver ARFI alone.CrossRefPubMed
60.
61.
Li N et al. Intrahepatic transit time predicts liver fibrosis in patients with chronic hepatitis B: quantitative assessment with contrast-enhanced ultrasonography. Ultrasound Med Biol. 2010;36(7):1066–75.CrossRefPubMed
62.
Ronot M et al. Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology. 2010;256(1):135–42.CrossRefPubMed
63.
Motosugi U et al. Multi-organ perfusion CT in the abdomen using a 320-detector row CT scanner: preliminary results of perfusion changes in the liver, spleen, and pancreas of cirrhotic patients. Eur J Radiol. 2012;81(10):2533–7.CrossRefPubMed
64.
Kanda T et al. CT hepatic perfusion measurement: comparison of three analytic methods. Eur J Radiol. 2012;81(9):2075–9.CrossRefPubMed
65.
Balassy C et al. Susceptibility-weighted MR imaging in the grading of liver fibrosis: a feasibility study. Radiology. 2014;270(1):149–58.CrossRefPubMed
66.
Feier D et al. Liver fibrosis: histopathologic and biochemical influences on diagnostic efficacy of hepatobiliary contrast-enhanced MR imaging in staging. Radiology. 2013;269(2):460–8.CrossRefPubMed
67.
Noren B et al. Separation of advanced from mild hepatic fibrosis by quantification of the hepatobiliary uptake of Gd-EOB-DTPA. Eur Radiol. 2013;23(1):174–81.CrossRefPubMed
68.
Verloh N et al. Impact of liver cirrhosis on liver enhancement at Gd-EOB-DTPA enhanced MRI at 3 Tesla. Eur J Radiol. 2013;82(10):1710–5.CrossRefPubMed
69.
Leroy V et al. Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol. 2004;99(2):271–9.CrossRefPubMed
70.
Walsh KM et al. Plasma levels of matrix metalloproteinase-2 (MMP-2) and tissue inhibitors of metalloproteinases -1 and -2 (TIMP-1 and TIMP-2) as noninvasive markers of liver disease in chronic hepatitis C: comparison using ROC analysis. Dig Dis Sci. 1999;44(3):624–30.CrossRefPubMed
71.
Schuftan GG, Bachem MG. Alpha2-macroglobulin reduces paracrine- and autocrine-stimulated matrix synthesis of cultured rat hepatic stellate cells. Eur J Clin Invest. 1999;29(6):519–28.CrossRefPubMed
72.
Mehta P et al. Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C. Am J Gastroenterol. 2008;103(4):928–36.CrossRefPubMed
73.
Jeffers LJ et al. Prospective evaluation of FIBROSpect II for fibrosis detection in hepatitis C and B patients undergoing laparoscopic biopsy. Gastroenterol Hepatol (N Y). 2007;3(5):367–76.
74.
Guha IN et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European Liver Fibrosis Panel and exploring simple markers. Hepatology. 2008;47(2):455–60.CrossRefPubMed
75.
Sanai FM et al. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen—negative patients with chronic hepatitis. Clin Gastroenterol Hepatol. 2013;11(11):1493–1499.e2.CrossRefPubMed
76.
Rosenberg WM et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004;127(6):1704–13.CrossRefPubMed
77.
78.
Myers RP et al. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci. 2003;48(1):146–53.CrossRefPubMed
79.
Halfon P et al. Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol. 2006;101(3):547–55.CrossRefPubMed
80.
Degos F et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol. 2010;53(6):1013–21.CrossRefPubMed
81.
82.
Kim BK et al. Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One. 2012;7(4):e35825.CrossRefPubMedPubMedCentral
83.
Adams LA et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem. 2005;51(10):1867–73.CrossRefPubMed
84.
Becker L et al. Validation of Hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol. 2009;7(6):696–701.CrossRefPubMed
85.••
Huang Y. et al. The ability of Hepascore to predict liver fibrosis in chronic liver disease: a meta-analysis. Liver Int. 2016. Hepascore is a clinically useful measure of liver fibrosis in patients with chronic liver disease, including those with CHB.
86.
Wai CT et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;38(2):518–26.CrossRefPubMed
87.
Castera L et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005;128(2):343–50.CrossRefPubMed
88.
Lackner C et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005;41(6):1376–82.CrossRefPubMed
89.
Schiavon LL et al. Simple blood tests as noninvasive markers of liver fibrosis in hemodialysis patients with chronic hepatitis C virus infection. Hepatology. 2007;46(2):307–14.CrossRefPubMed
90.
91.
Lieber CS et al. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol. 2006;101(7):1500–8.CrossRefPubMed
92.
Udell JA et al. Does this patient with liver disease have cirrhosis? Jama. 2012;307(8):832–42.CrossRefPubMed
93.
Zhang Z et al. The diagnostic accuracy and clinical utility of three noninvasive models for predicting liver fibrosis in patients with HBV infection. PLoS One. 2016;11(4):e0152757.CrossRefPubMedPubMedCentral
94.••
Ray KW et al. Evaluation of APRI and FIB-4 scoring systems for non-invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773–80. APRI and FIB-4 demonstrated to be poor diagnostic tools for the assessment of hepatic fibrosis, especially in gauging liver fibrosis improvements following antiviral therapy.CrossRef
95.
Wang H et al. Comparison of FIB-4 and APRI in Chinese HBV-infected patients with persistently normal ALT and mildly elevated ALT. J Viral Hepat. 2013;20(4):e3–10.CrossRefPubMed
96.
Teshale E et al. APRI and FIB-4 are good predictors of the stage of liver fibrosis in chronic hepatitis B: the Chronic Hepatitis Cohort Study (CHeCS). J Viral Hepat. 2014;21(12):917–20.CrossRefPubMed
97.
Kim BK et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int. 2010;30(4):546–53.CrossRefPubMed
98.
Li J et al. The validity of serum markers for fibrosis staging in chronic hepatitis B and C. J Viral Hepat. 2014;21(12):930–7.CrossRefPubMed
99.
Lu Q. et al. Stiffness value and serum biomarkers in liver fibrosis staging: study in large surgical specimens in patients with chronic hepatitis B. Radiology. 2016:151229.
100.
Imperiale TF et al. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol. 2000;95(9):2328–32.CrossRefPubMed
101.
Giannini E et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163(2):218–24.CrossRefPubMed
102.
Sheth SG et al. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998;93(1):44–8.CrossRefPubMed
Metadaten
Titel
Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus
verfasst von
Blanca Lizaola
Alan Bonder
Elliot B. Tapper
Nezam Afdhal
Publikationsdatum
20.07.2016
Verlag
Springer US
Erschienen in
Current Hepatology Reports / Ausgabe 4/2016
Elektronische ISSN: 2195-9595
DOI
https://doi.org/10.1007/s11901-016-0311-0

Weitere Artikel der Ausgabe 4/2016

Current Hepatology Reports 4/2016 Zur Ausgabe

Hepatitis B (JK Lim, Section Editor)

Future Therapy for HBV: Role of Cell Cycle Inhibitors

Hepatitis B (JK Lim, Section Editor)

Future Therapy for Hepatitis B Virus: Role of Nucleos(t)ide Analogues and Pegylated Interferon Therapy

Hepatic Cancer (A Singal and A Mufti, Section Editors)

Looking Forward: Surgical Resection, Liver Transplantation, and Hilar Cholangiocarcinoma

Hepatitis C (J Ahn, Section Editor)

Hepatitis C and Hepatocellular Carcinoma

Hepatitis B (JK Lim, Section Editor)

Current Management of Hepatitis B in 2016

Hepatitis B (JK Lim, Section Editor)

Future Therapy for Hepatitis B Virus: Role of Immunomodulators

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise